Neoplasm.News

XPO1 inhibitor × Plasma cell × Clear all

2 Announcements

FDA approves selinexor for refractory or relapsed multiple myeloma

Trial: BOSTON
Drugs: XPOVIO (selinexor) · XPO1 inhibitor, bortezomib · Proteasome inhibitor
Condition: Plasma cell

FDA grants accelerated approval to selinexor for multiple myeloma

Trial: STORM
Drug: XPOVIO (selinexor) · XPO1 inhibitor
Condition: Plasma cell